{"analyses":[{"groupDescription":"Null hypothesis was no difference between treatment groups","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.806","pValueComment":"This analysis was conducted contingent on a statistically significant difference in the primary outcome, and adjusted to an a priori threshold for statistical significance at a 4% level for a multiple comparison involving objective tumor response","statisticalComment":"Stratified by baseline IVRS ECOG performance status and geographic region","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.1","upperLimit":"7.7","value":"6.4"},{"groupId":"OG001","lowerLimit":"4.9","upperLimit":"7.6","value":"6.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"232"}],"units":"Participants"}],"description":"Kaplan-Meier estimates of median time from randomization to death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Panitumumab plus best supportive care (BSC). Panitumumab was administered by intravenous infusion at a dose of 6 mg/kg once every 2 weeks until participants developed progressive disease or were unable to tolerate study drug.","id":"OG000","title":"Panitumumab Plus BSC"},{"description":"Best supportive care defined as the best care available as judged appropriate by the investigator and according to institutional guidelines, including antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any symptomatic therapy as clinically indicated. For the purpose of this study, best supportive care does not include anti-neoplastic chemotherapy.","id":"OG001","title":"BSC Alone"}],"paramType":"MEDIAN","populationDescription":"Intention-to-treat (ITT)","reportingStatus":"POSTED","timeFrame":"From randomization until the data cut-off date for overall survival of 15 March 2006. The median actual follow-up time was 30 weeks for the panitumumab plus BSC group and 31 weeks for the BSC alone group.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}